Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 12Recruiting 12Completed 10Not yet recruiting 9Active not recruiting 8Unknown 4Withdrawn 3Suspended 1Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 1

Interventions

Specimen Handling 9Magnetic Resonance Spectroscopy 7Biopsy 6Nivolumab 4Capecitabine 4Bevacizumab 4Radiosurgery 3Paclitaxel 3Irinotecan 3Fluorouracil 3Everolimus 3Docetaxel 3Cyclophosphamide 3Cisplatin 3trifluridine tipiracil drug combination 2spartalizumab 2pembrolizumab 2lenvatinib 2decitabine and cedazuridine drug combination 2daratumumab 2Vincristine 2Taxes 2Radiation 2Prednisone 2Pemetrexed 2Oxaliplatin 2Mitoxantrone 2Leucovorin 2Etoposide 2Epirubicin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Suspended × selinexor × Clear all
NCT04661137 2026-02-10

A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma

Hackensack Meridian Health

Phase 2 Suspended
96 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡